Skip to content

Evaluation of the Improvement Effects of Oligosaccharide Intake on the Concentration of Anti-Aging Compounds in Blood and Feces

Evaluation of the Improvement Effects of Oligosaccharide Intake on the Concentration of Anti-Aging Compounds in Blood and Feces - Evaluation of the Improvement Effects of Oligosaccharide Intake on the Concentration of Anti-Aging Compounds in Blood and Feces

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000052311
Enrollment
20
Registered
2024-09-26
Start date
2023-09-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Male adults

Interventions

Consumption of the test foods for 4 weeks

Sponsors

CPCC Company Limited
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Healthy males aged 60 to 75 years. 2. Subjects who defecate every morning. 3. Subjects who can give informed consent to partake in this research, after being provided with an explanation of the protocol detail.

Exclusion criteria

Exclusion criteria: 1. Subjects who take habitually (not less than 3 times a week) in the Food for Specified Health Uses (FOSHU) or Foods with Function Claims or supplementary food or health foods or yogurts or lactic acid bacteria beverages or fiber-fortified foods, oligosaccharides which might affect the test results. 2. Subjects who have taken the following medications that may affect the study for 1 month prior to the pre-test, and those who cannot limit their use from the pre-test to the time of the 4W test. 2.1 Intestinal preparations 2.2 Antibiotics 2.3 Vitamins, including vitamin B3 3. Subjects who are in the habit of smoking, or have been in the habit of smoking within the past year. 4. Subjects with excessive alcohol intake. 5. Subjects who are participating the other clinical tests. Subjects who participated within 4-weeks prior to the current study and/or who plan to participate the other clinical tests. 6. Subjects with serious or progressive preexisting illnesses or symptoms. 7. Subjects with previous and/or current medical history of serious diseases in heart, liver, kidney and/or digestive organs. 8. Subjects having some kind of drug and/or food allergy. 9. Subjects who donated blood or component (200 mL) within the last 1 months. 10. Subjects who donated his blood (400 mL) within the last 3 months. 11. Subjects who being collected in total of his blood (1200 mL) within the last 12 months and in this research. 12. Subjects deemed unsuitable for participation in the trial by the principal investigator or sub-investigator.

Design outcomes

Primary

MeasureTime frame
NAD+-related metabolites in feces. NAD+-related metabolites in blood.

Secondary

MeasureTime frame
Comprehensive analysis of fecal flora, total bacterial count. Fecal water content. Organic acid concentration in feces. Defecation status. Abdominal symptoms at times other than defecation.

Countries

Japan

Contacts

Public ContactMakoto Ichinohe

CPCC Company Limited Clinical Planning Department

cpcc-contact@cpcc.co.jp03-6225-9001

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026